


PHARMACEUTICAL 2022

Annovis Bio Inc. Rank 179 of 475





PHARMACEUTICAL 2022

Annovis Bio Inc. Rank 179 of 475

The relative strengths and weaknesses of Annovis Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Annovis Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 257% points. The greatest weakness of Annovis Bio Inc. is the variable Net Income, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 235% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	46,001
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,507
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	50
Property and Equipment	0
Research and Development	8,479
Revenues	0
Selling, General and Administrative Expense	6,058

Output Variable	Value in 1000 USD
Assets	46,001
Liabilities	1,507
Expenses	14,537
Stockholders Equity	44,495
Net Income	-14,487
Comprehensive Net Income	-14,487
Economic Capital Ratio	-42%